parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in thymic myoid cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 16565

OSBPL6 in dopamine neurons, braak+0.63 (p 0.067) → +0.20 (p 0.597)receipt 16573
OSBPL6 in astrocytes, braak+0.62 (p 0.073) → -0.36 (p 0.344)receipt 16572

receipt 16573: OSBPL6 in dopamine neurons, braak

power: full sample +0.14 (p 0.579, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.646, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.08 (p 0.754, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.30, sign flips 0; without severely affected donors +0.14 (p 0.579, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for OSBPL6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16572: OSBPL6 in astrocytes, braak

power: full sample +0.18 (p 0.465, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.19 (p 0.455, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.20 (p 0.429, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.31, sign flips 0; without severely affected donors +0.18 (p 0.465, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for OSBPL6 in astrocytes.

case closed: nothing better to follow up.

loading the receipts